{
  "docId": "019de073-a38b-741c-ac33-1ee77869cf6c",
  "docSlug": "1556a4546991601fbfe098864d52433b",
  "documentTitle": "ATAI | Investor Presentation Deck | 36 slides",
  "authorId": "atai",
  "authorName": "atai Life Sciences",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2022-10-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 14,
  "pageCount": 36,
  "prevPage": 13,
  "nextPage": 15,
  "slideType": "executive_summary",
  "function": "summarize",
  "density": "overcrowded",
  "nDataPoints": 12,
  "notes": "The slide uses a split-layout with a dark sidebar for key facts and a white main area for clinical data visualization.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de073-a38b-741c-ac33-1ee77869cf6c/14",
  "deckHref": "/decks/019de073-a38b-741c-ac33-1ee77869cf6c",
  "deckJsonHref": "/decks/019de073-a38b-741c-ac33-1ee77869cf6c.json",
  "deckAnchorHref": "/decks/019de073-a38b-741c-ac33-1ee77869cf6c#slide-14",
  "components": [
    {
      "bbox": {
        "h": 0.45,
        "w": 0.28,
        "x": 0.37,
        "y": 0.33
      },
      "kind": "chart",
      "text": "MADRS score over time",
      "attrs": null,
      "subkind": "line",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "1cae96cc-3eea-41bc-a505-597caa787a3d",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.45,
        "w": 0.28,
        "x": 0.68,
        "y": 0.33
      },
      "kind": "chart",
      "text": "CADSS score over time",
      "attrs": null,
      "subkind": "line",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "89568add-2d5a-411b-bc0d-4d1409730865",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.75,
        "w": 0.31,
        "x": 0.04,
        "y": 0.16
      },
      "kind": "list",
      "text": "OWNERSHIP 58.9% PRODUCT Subcutaneous R-ketamine (PCN-101) PHARMACOLOGY Glutamatergic modulator PRODUCT FEATURES Rapid-acting, nonpsychedelic antidepressant with potential for at home use INDICATIONS Primary: Treatment Resistant Depression Potential: Substance Use Disorder CURRENT STATUS Phase 1 trial showed safety and tolerability of R-ketamine at doses of up to 150mg, Phase 2a proof-of-concept study initiated in Q3 2021 INTELLECTUAL PROPERTY Issued methods of use of R-ketamine for treatment of depressive symptoms HIGHLIGHT Third party study: Single IV dose (0.5 mg/kg) of R-ketamine led to a rapid and sustained decrease in MADRS in patients with TRD; dissociation was nearly absent",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "6d5cc838-ebc6-4b75-80c5-5551b061f6b9",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.58,
        "x": 0.37,
        "y": 0.91
      },
      "kind": "source-note",
      "text": "Note: MADRS = Montgomery-Asberg Depression Rate Scale, CADSS = Clinician-administered dissociative states scale, IV = Intravenous, PBO = Placebo. (1) Unless otherwise indicated herein, ownership percentage based on ownership of securities with voting rights as of June 30th, 2022. Perception does not give effect to the shares of common stock issuable after giving full effect to the anti-dilution feature of the Stock Purchase Agreement, which would not impact our majority position in Perception. (2) Leal et al., “Intravenous arketamine for treatment-resistant depression: open-label pilot study” (2020) (3) Singh et al. “Intravenous Esketamine in Adult Treatment-Resistant Depression”, Biological Psychiatry (2016)",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "b184d413-5408-4bcc-b20d-722f01935e01",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.07,
        "w": 0.58,
        "x": 0.37,
        "y": 0.07
      },
      "kind": "title",
      "text": "We aim to develop PCN-101 as a rapid acting antidepressant with potential for at-home use",
      "attrs": null,
      "subkind": "action-title",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "da3fb663-393c-4b8b-88b6-9f0d731a0f6d",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.13,
        "x": 0.04,
        "y": 0.07
      },
      "kind": "title",
      "text": "SUMMARY",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "6ac33e4f-9a0b-4584-9ffe-f46355f52b9f",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Executive summary",
      "slug": "executive-summary",
      "agent": null,
      "layer": "slide",
      "matchId": "c75d00e3-3368-41b1-bb63-97f8d7d9de26",
      "evidence": "The slide is titled 'We aim to develop PCN-101 as a rapid acting antidepressant with potential for at-home use' and has a type labeled as 'executive_summary'.",
      "confidence": 0.9
    }
  ],
  "frameworks": [],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}